18 results about "Immune adsorption" patented technology

The invention relates to a detection method, in particular to a method for rapidly detecting alpha and beta-lactoglobulin in auxiliary material lactose based on a microarray chip technology. On the basis of an indirect competitive enzyme-linked immunosorbent assay principle and a silver enhanced developing technology, a high-sensitivity microarray chip detection platform is successfully constructed by virtue of a biological chip scanner, and rapid quantitative analysis of alpha-lactalbumin and beta-lactoglobulin in the auxiliary material lactose for injection is realized. According to the method, an antigen-antibody specific recognition mechanism and a nano-silver signal amplification mechanism are integrated, and the detection efficiency and sensitivity are remarkably improved through the high-throughput layout of the microarray chip. In the aspect of methodology performance, the technology has the remarkable advantages of simple and convenient operation process, short detection time, high sample treatment flux, excellent specificity (CRlt; 1%) and the like.

The invention belongs to the technical field of biological medicines, and particularly relates to a dissociation liquid applied to an aluminum adjuvant adsorption influenza vaccine and a method for measuring the antigen content. The dissociation liquid disclosed by the invention is prepared from a potassium phosphate salt solution, diethanol amine, TritonX-100, tween-20, dodecyl dimethyl betaine and water. The dissociation liquid is excellent in dissociation efficiency, the dissociation recovery rate of the dissociation liquid to H1N1, H3N2 and BV type influenza vaccine hemagglutinin reaches 106%-110%, the antigen activity can be effectively protected, operation is easy and convenient, adaptability is wide, a dissociated sample can be directly used for mainstream detection methods such as a one-way immunodiffusion test, an enzyme-linked immunosorbent assay and a high performance liquid chromatography method, and the dissociation liquid has good application prospects. The precise quantification of the antigen content in the aluminum adjuvant adsorption influenza vaccine is realized, and a reliable technical support is provided for vaccine quality control.

The invention relates to key antigen epitope screening, in particular to an echovirus 18 type key antigen epitope peptide and application thereof. The result of an enzyme-linked immunosorbent assay shows that Epitope 1 (SEQ ID NO: 1) can be effectively combined with E18-VP1 antiserum, and the combining capacity is obviously higher than that of Epitope 2 in a blank control and a negative result, so that one antigen epitope peptide is screened based on the complete sequence of the echovirus 18-VP1, and the antigen epitope peptide has important guiding significance for research and development of echovirus 18 vaccines.

The application provides a screening method of human amniotic membrane mesenchymal stem cells (hAMSCs) with bone regeneration promoting potential, and uses the protein level of transmembrane protein 119 (TMEM119) as a functional index of the bone regeneration promoting ability of the hAMSCs, and uses an enzyme-linked immunosorbent assay (ELISA) to detect the TMEM119 protein concentration in a lysis solution prepared from 1×10 7 The application uses the TMEM119 protein concentration not lower than 15000 pg / mL as a screening standard of the hAMSCs with bone regeneration promoting potential, and screens the hAMSCs with significant bone regeneration promoting potential from different batches of hAMSCs, so that the hAMSCs meeting the screening standard of the application have obvious bone formation promoting potential, and the technical problem that the hAMSCs with bone regeneration promoting potential are difficult to be accurately identified and screened in clinical transformation is solved.

The invention discloses an application of nitric oxide synthase neurons in an island leaf cortex II layer in preparation of a medicine for treating osteoporosis, and systematically reveals a nerve stress induced bone metabolism imbalance mechanism by constructing a chronic heterologous pressure stress mouse model and combining an enzyme-linked immunosorbent assay and a high-resolution micro-CT (Computed Tomography) technology; the method comprises the following steps: accurately positioning specific nerve connection between nNOS neurons of an island leaf cortex II layer and bone tissues for the first time by adopting a reverse cross-polysynaptic virus tracing technology, and determining that the region is a key central target point regulated and controlled by a brain-bone axis; the activity of target neurons is specifically intervened through a chemical genetics technology, it is proved that activation can induce the phenotype of osteoporosis, and pathologic indexes are remarkably improved through inhibition.

The invention discloses a camel source single-domain antibody CB3 for recognizing linear B cell epitope in clostridium difficile methylase CamA and application of the camel source single-domain antibody CB3. The nucleotide sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 1, and the amino acid sequence of the camel source single-domain antibody CB3 is as shown in SEQ ID NO: 2. The camel source single-domain antibody CB3 disclosed by the invention has the advantages of strong specificity, high sensitivity, good accuracy and the like, and it is proved that the camel source single-domain antibody CB3 can be used for detecting recombinant expressed CD-CamA and endogenous CD-CamA by methods such as enzyme-linked immunosorbent assay (ELISA) and western blot hybridization (WB).

A protein detection method and a detection device as well as use are provided. The protein detection method includes: fixing a probe type graphic encoding chip coupled with a specific capture antibody in the detection device, and meanwhile respectively sealing SAPE and a detection antibody in the detection device; and when in detection, performing detection and analysis based on an enzyme linked immunosorbent assay (ELISA) principle through the probe-type graphic encoding chip after the detection antibody and the SAPE are respectively dissolved, so as to obtain protein quantitative analysis results. In the protein detection method, the adopted Lab-in-Tip technology can complete processes such as sampling, washing, detection antibody hybridization, washing and binding of fluorescence labeled streptavidin and a biotin labeled detection antibody in such the Lab-in-Tip device, and has the advantages of multiplexed detection, such as quick completion, convenience, high flexibility, good specificity, few sample capacity and wide detection range.

This invention relates to a prothioconazole hapten, artificial antigen, polyclonal antibody, and their preparation methods and applications. The structural formula of the prothioconazole hapten is shown in formula (1). When the prothioconazole hapten, artificial antigen, and polyclonal antibody of this invention are used for indirect competitive enzyme-linked immunosorbent assay (ELISA) to detect prothioconazole residues, the sample pretreatment is simple, the detection results are accurate, the detection time is short and the cost is low. At the same time, the operation is simple and samples can be processed in batches, which is conducive to the development of field work.

This invention belongs to the field of biomedical technology, specifically relating to a dissociation solution for aluminum adjuvant-adsorbed influenza vaccines and a method for determining antigen content. The dissociation solution of this invention is composed of potassium phosphate solution, diethanolamine, Triton X-100, Tween-20, dodecyl dimethyl betaine, and water. This dissociation solution exhibits excellent dissociation efficiency, achieving a recovery rate of 106%-110% for hemagglutinin from H1N1, H3N2, and BV influenza vaccines. It effectively protects antigen activity and is simple to operate with wide applicability. The dissociated sample can be directly used for mainstream detection methods such as one-way immunodiffusion assay, enzyme-linked immunosorbent assay, and high-performance liquid chromatography, enabling precise quantification of antigen content in aluminum adjuvant-adsorbed influenza vaccines and providing reliable technical support for vaccine quality control.

The invention discloses a double-nano-enzyme probe for detecting beta-amyloid oligomer, a kit based on the double-nano-enzyme probe as well as a preparation method and application of the double-nano-enzyme probe. The double nano-enzyme probe disclosed by the invention comprises a Si (at) Ag / Pt nano-enzyme probe functionalized by a beta-amyloid protein oligomer aptamer; the Ag / Pt nano-enzyme probe is hybridized and combined with the Si (at) Ag / Pt nano-enzyme probe functionalized by the beta-amyloid protein oligomer aptamer. The invention further discloses a preparation method of the double-nano-enzyme probe. The double-nano-enzyme probe disclosed by the invention can be used for constructing a nano-enzyme-linked immunosorbent assay (NLISA) platform with high sensitivity and high specificity, and accurate and quantitative detection of the beta-amyloid oligomer is realized through an antibody-antigen-aptamer sandwich method and a DNA cross-linking amplification strategy.

The idea of the patent includes a new principle, which is the detection of immune complexes using ELISA technology, which is a new and modern principle that is added to the four principles of ELISA, the new principle (the fifth ELISA) depends on detection of immune complexes, which consist of two different parts of proteins (an antigen - an antigen). This complex can be detected through this new principle, and it was applied to the immune complex (thyroid-stimulating hormone receptors and antibodies formed against it) Hashimoto's patients. It was considered an example of applying this theory, the immune complex was actually detected, its concentration determined, and compared to other techniques. A standard solution specially designed for this purpose was used to prove this theory. In this patent, a new kit is specifically designed to detect these immune complexes. Immune complex, the group is considered successful. In terms of use.

A method and corresponding kit for detecting Sjögren's Disease or predicting labial salivary gland biopsy results. The method includes evaluating an individual for the presence of one or more peptides or whole proteins or fragments thereof having an amino acid sequence selected from SEQ ID NOS: 1-67. The method and kit may be formatted as an enzyme-linked immunosorbent assay (ELISA).

Disclosed here is a device and method to detect the presence or absence of a target molecule by detecting fluorescence resonance energy transfer (FRET) signal generated when two labeled probes bind to the target molecule. The method is a sandwich enzyme-linked immunosorbent assay (ELISA) or a nucleic acid hybridization assay.

The invention discloses a nano modification and high-density coating process for the surface of an enzyme-linked immunosorbent assay plate. The composition comprises an interface self-assembly bottom layer solution containing tannic acid and branched polyethyleneimine, and a dynamic gating functionalized buffer solution containing sodium tetraborate, D-mannitol and trehalose. The process comprises the following steps: firstly, constructing a supramolecular bottom layer on the surface of polystyrene, and then forming a boric acid-mannitol gating interface through non-washing drying; after the antibody is added, the Fc segment sugar chain and boric acid are subjected to competitive replacement reaction, so that mannitol is replaced, and the oriented high-density fixation of the antibody is realized. According to the invention, the problems of random antibody direction and weak binding force in traditional physical adsorption are solved, the antibody immobilization amount and detection sensitivity of the elisa plate are remarkably improved, and the elisa plate has good storage stability.

The invention discloses a nano antibody or an antigen binding fragment, a coding gene and a recombinant expression vector of a targeted porcine circovirus type 2 Rep protein, and application of the nano antibody or the antigen binding fragment, the coding gene and the recombinant expression vector as a reagent or a kit. The nanobody or the antigen binding fragment thereof comprises at least one complementary determinant selected from the group consisting of CDR1, CDR2 and CDR3. The high-affinity nano antibody molecule aiming at the porcine circovirus type 2 (PCV2) Rep protein, which is constructed by the invention, is combined with a competitive enzyme-linked immunosorbent assay system, so that high-sensitivity, high-specificity and high-stability quantitative detection on the anti-PCV2 antibody in porcine serum can be effectively realized. According to the technical scheme, multiple limitations of a traditional antibody detection method in the aspects of stability, production consistency, detection flux and cross reactivity are broken through, and a set of standardized diagnosis platform suitable for grass-roots breeding institutions, large-scale epidemiological screening and vaccine immune effect evaluation is constructed.

The invention relates to a vaccine, in particular to a chimeric virus-like particle vaccine based on an echovirus 30 type key epitope as well as a preparation method and application of the chimeric virus-like particle vaccine. The invention provides a method for screening antigen epitopes, which comprises the following steps: firstly, predicting the antigen epitope of capsid protein VP1 through bioinformatics analysis, and then screening epitopes which can be effectively combined with anti-VP1 complete sequence serum through enzyme-linked immunosorbent assay. Results of an enzyme-linked immunosorbent assay show that the expressed antigen epitope peptide E30-6 (SEQ ID NO: 2) can be strongly combined with E30 VP1 antiserum, so that one high-immunogenicity antigen epitope peptide is screened based on the complete sequence of the echovirus 30 VP1, which has important guiding significance for research and development of echovirus 30 vaccines. Besides, the HBc-E30-6 vaccine is designed and prepared based on the epitope, the HBc-E30-6 vaccine is high in purity and can be self-assembled into VLP nanoparticles, and more importantly, serum immunized by the vaccine can effectively neutralize the echovirus 30.

The invention discloses a hepatitis A vaccine virus titer trace detection method, a kit and application. Comprising the following steps: inoculating human diploid cells into a porous cell culture plate, and culturing to form monolayer cells; inoculating a to-be-detected hepatitis A virus sample into the porous cell culture plate with monolayer cells, carrying out virus adsorption and culture, marking as an experimental group, and taking human diploid cells not inoculated with the virus sample as a negative control group; adding acetone into the experimental group and the negative control group for incubation so as to lyse cells and fix hepatitis A viruses and antigens thereof; detecting by adopting an enzyme-linked immunosorbent assay, and calculating according to a detection result to obtain the virus titer of the hepatitis A virus sample to be detected. The method is simple and convenient to operate, a virus extraction step in a traditional method is omitted, reagents are remarkably saved, the detection flux is improved, and the method is highly related to results of a pharmacopoeia method and is suitable for vaccine process research and development and quality control.

Compositions including Wb4 protein, or antigenic portions thereof, are provided. Such compositions are useful, for example, for detecting agents of lymphatic filariasis, such as Wuchereria bancrofti and / or Brugia spp. Nucleic acids and vectors including the Wb4 protein, or antigenic portion thereof, are also provided, as well as host cells including the nucleic acids or vectors. Further provided are methods of detecting antibodies to Wb4 in a sample from a subject, including luciferase immunoprecipitation assays, ELISA, or lateral flow assays.